Products
An array of non-invasive solutions for diagnosis, screening and monitoring
LIVERFASt™ is a blood based diagnostic test that combines 10 biomarkers and algorithm technology to determine the fibrosis, activity and steatosis stages of the liver.
Biomarkers
- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Total Bilirubin
- GGT
- ALT (P5P)
- AST (P5P)
- Fasting Glucose
- Triglyceride
- Total Cholesterol
LIVERFACt is a component of LIVERFASt™ that utilizes only 6
out of the 10 biomarkers to provide results for fibrosis and
activity stages of the liver. LIVERFACt enables early
diagnosis of liver disease in patients with Hepatitis B and
Hepatitis C.
Biomarkers
- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Total Bilirubin
- GGT
- ALT (P5P)
SteatoTEST applies the similar 10 biomarkers that LIVERFASt™ utilizes and provides results for the staging of liver steatosis or also known as fatty liver.
Biomarkers
- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Total Bilirubin
- GGT
- ALT (P5P)
- AST (P5P)
- Fasting Glucose
- Triglyceride
- Total Cholesterol
LIVERFASt select is a risk stratification tool for fatty liver disease that utilizes a combination of basic blood biomarkers and algorithm technology.
LIVERFASt select helps healthcare professionals and organizations screen patient populations for individuals with high fatty liver risk.
HealthFACTR employs technology to predict risk – providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease.
HealthFACTR enables action-oriented recommendations which allows healthcare professionals and healthcare organizations to determine patients’ risk levels and drive better patient care.
